Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

No abstract is available for this paper.

• Publication year

  2003

• Venue

  British Journal of Haematology

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.2003.04240.xPMID 12670352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

  2001cited by this paper
• Comparison between deferoxamine and deferiprone (L1) in iron‐loaded thalassemia patients

  2001cited by this paper
• Combined oral and parenteral iron chelation in beta thalassaemia major.

  2000cited by this paper
• Deferiprone

  1999cited by this paper
• Combined therapy with deferiprone and desferrioxamine

  1998cited by this paper
• Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

  1998cited by this paper
• Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

  1998cited by this paper

• Efficacy and safety of deferiprone for thalassemia: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Association of serum ferritin trends with liver enzyme patterns in β-thalassemia major: A longitudinal correlational study

  2024cites this paper
• Stealing Survival: Iron Acquisition Strategies of Mycobacterium tuberculosis.

  2024cites this paper
• An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes

  2023cites this paper
• Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict

  2023cites this paper
• Combination chelation therapy

  2023cites this paper
• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

  2023cites this paper
• COMPARATIVE EFFICACY AND SAFETY OF ORAL IRON CHELATORS AND THEIR NOVEL COMBINATION IN CHILDREN WITH THALASSEMIA

  2022cites this paper
• Cerebral Iron Deposition in Neurodegeneration

  2022cites this paper
• Diagnosis and treatment of metal poisoning general aspects

  2022cites this paper
• Chelation Combination—A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper?

  2022cites this paper
• Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children

  2021cites this paper
• Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review

  2020cites this paper
• Non-invasive prenatal diagnosis of thalassemia through multiplex PCR, target capture and next-generation sequencing

  2020cites this paper
• Comparative study of Deferiprone versus Deferiprone with Deferasirox as iron chelation therapy in Thalassemic children

  2020cites this paper
• Comparison of Deferoxamine, Deferiprone and Deferasirox Iron-Chelating Agents in Reducing Serum Ferritin Levels in Patients with Thalassemia Major

  2020cites this paper
• Deferiprone exerts a dose‐dependent reduction of liver iron in adults with iron overload

  2019cites this paper
• Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox

  2019cites this paper
• An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload

  2019cites this paper
• Cardiac Iron Loading and Myocardial T2*

  2019cites this paper
• Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox

  2019cites this paper
• The Role of Deferiprone in Iron Chelation.

  2018cites this paper
• Effect of Deferiprone versus Deferiprone with Deferasirox in Iron Chelation Therapy of Thalassemia Children

  2018cites this paper
• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

  2018cites this paper
• Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis

  2018cites this paper
• The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major

  2017cites this paper
• Beneficial role of deferasirox and deferiprone in the mobilization of arsenic and recovery of iron in rat tissues

  2017cites this paper
• Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia

  2016cites this paper
• Morbidities in non‐transfusion‐dependent thalassemia

  2016cites this paper
• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.

  2016cites this paper
• Guidance for Clinical Treatment of Metal Poisonings—Use and Misuse of Chelating Agents

  2016cites this paper
• Chelating Therapy in Metal Storage Diseases

  2016cites this paper
• Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia

  2016cites this paper
• Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial

  2016cites this paper
• Iron chelation in the treatment of neurodegenerative diseases.

  2016cites this paper
• THERAPEUTIC ADVANCEMENTS IN MANAGEMENT OF IRON OVERLOAD-A REVIEW Review Article

  2015cites this paper
• Chelation in metal intoxication--Principles and paradigms.

  2015cites this paper
• Chapter 23 – Metal Antagonists

  2015cites this paper
• Comparative efficacy of deferiprone, deferoxamine and combination of deferiprone and deferoxamine on serum ferritin value in Beta-Thalassemia patients

  2015cites this paper
• Chapter 23 – Diagnosis and Treatment of Metal Poisoning: General Aspects

  2015cites this paper
• Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions

  2015cites this paper
• A Systematic Review and Meta-Analysis of Deferiprone Monotherapy and in Combination with Deferoxamine for Reduction of Iron Overload in Chronically Transfused Patients with β-Thalassemia

  2014cites this paper
• Combined Chelation Therapy with Daily Oral Deferiprone and Twice-Weekly Subcutaneous Infusion of Desferrioxamine in Children with β-Thalassemia: 3-Year Experience

  2014cites this paper
• Toxic Metals: Health Effects, and Therapeutic Measures

  2014cites this paper
• From the American Heart Association -Thalassemia Major: A Consensus Statement β Cardiovascular Function and Treatment in

  2014cites this paper
• When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

  2013cites this paper
• 3.35 – Chelation Therapy

  2013cites this paper
• Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

  2013cites this paper
• Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.

  2013cites this paper
• Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion

  2013influential citation
• Oral deferiprone for iron chelation in people with thalassaemia.

  2013cites this paper
• Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials

  2013cites this paper
• Clinical Use of Iron Chelators

  2012cites this paper
• Iron mobilization using chelation and phlebotomy.

  2012cites this paper
• The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients

  2012cites this paper
• Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.

  2012cites this paper
• dendritic cells Toward the identification of a tolerogenic signature in IDO-competent

  2012cites this paper
• Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

  2011cites this paper
• THE BEST IRON CHELATION THERAPY IN MAJOR THALASSEMIA PATIENTS IS COMBINATION OF DESFERRIOXAMINE AND DEFERIPRONE

  2011cites this paper
• Transfusion Therapy in β Thalassemia and Sickle Cell Disease

  2011cites this paper
• AHA Consensus Statement

  2011cites this paper
• Deferoxamine Versus Combined Therapy for Chelating Liver, Spleen and Bone Marrow Iron in β-Thalassemic Patients: A Quantitative Magnetic Resonance Imaging Study

  2010cites this paper
• Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study

  2010cites this paper
• Dual-echo TFE MRI for the assessment of myocardial iron overload in beta-thalassemia major patients.

  2010cites this paper
• Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.

  2010cites this paper
• Effect of combination therapy of hydroxyurea with l‐carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with β‐thalassemia intermedia

  2010cites this paper
• COMPARISON BETWEEN DEFEROXAMINE AND COMBINED THERAPY WITH DEFEROXAMINE AND DEFERIPRONE IN IRON OVERLOADED THALASSEMIA PATIENTS

  2010cites this paper
• An update on disordered iron metabolism and iron overload

  2010cites this paper
• Experience with Combination Therapy of Deferiprone and Desferrioxamine in β-Thalassemia Major Patients with Iron Overload at Maternity and Children Hospital, Al Madinah Al Munawarah, Saudi Arabia

  2010cites this paper
• Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years

  2010cites this paper
• Combined iron chelation therapy

  2010cites this paper
• The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study

  2010cites this paper
• Lipid Profile in Thalassemia Major Patients on Desferrioxamine Therapy

  2009cites this paper
• Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.

  2009cites this paper
• siderosis beta-thalassemia major patients with asymptomatic myocardial Randomized controlled trial of deferiprone or deferoxamine in

  2009cites this paper
• Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.

  2009cites this paper
• Optimizing iron chelation strategies in beta-thalassaemia major.

  2009cites this paper
• Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients

  2009cites this paper
• Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier

  2009cites this paper
• Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

  2009cites this paper
• Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

  2009cites this paper
• Deferiprone Chelation Therapy for Thalassemia Major

  2009cites this paper
• Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.

  2008cites this paper
• Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience

  2008cites this paper
• Effects of Combined Deferiprone and Deferoxamine Chelation Therapy on Iron Load Indices in β-Thalassemia

  2008cites this paper
• Beta-thalassemia intermedia: an overview.

  2008cites this paper
• Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders

  2008cites this paper
• Current status in iron chelation in hemoglobinopathies.

  2008cites this paper
• Long-term efficacy and safety of deferasirox.

  2008cites this paper
• Congestive Heart Failure and Treatment in Thalassemia Major

  2008cites this paper
• Red blood cell enzyme disorders: an overview.

  2008cites this paper
• Four‐year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β‐thalassaemia major: comparison between different chelation regimens

  2007cites this paper
• Oral deferiprone for iron chelation in people with thalassaemia.

  2007cites this paper
• 23 – Metal antagonists

  2007cites this paper
• Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.

  2007cites this paper
• Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with β-thalassemia major

  2007cites this paper
• Light and shadows in the iron chelation treatment of haematological diseases

  2007influential citation
• A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major

  2007cites this paper
• Urinary Iron Excretion in Young Thalassemic Patients Receiving Combined Chelation Treatment With Deferoxamine and Deferiprone

  2007cites this paper
• Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.

  2007cites this paper